Key Details
Price
$8.67Last Dividend
$0.25TTM Dividend Yield
2.88%Annual Revenue
$31.34 MAnnual EPS
-$1.14Annual ROE
86.32%Beta
0.04Events Calendar
Next earnings date:
Feb 28, 2025Recent quarterly earnings:
Oct 15, 2024Recent annual earnings:
Feb 28, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
Nov 15, 2024Next split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
29 Aug '22 Maxim Group
BuyMarket Data
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Dividend
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
0
Profitability
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Efficiency
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Valuation
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Liquidity
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Cash Flow
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Institutional Ownership
Cord Blood Banking Leader Cryo-Cell Reports Fiscal Third Quarter 2024 Financial Results
CCEL
businesswire.com15 October 2024
OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC Symbol: CCEL) (the “Company”), the world's first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal third quarter ended August 31, 2024. Financial Results Revenue Consolidated revenues for the third quarter of fiscal 2024 were $8.07 million compared to $7.87 million for the third quarter of fiscal 2023. Net Income The Company reported net income for the three months e.
FAQ
- What is the primary business of Cryo-Cell International?
- What is the ticker symbol for Cryo-Cell International?
- Does Cryo-Cell International pay dividends?
- What sector is Cryo-Cell International in?
- What industry is Cryo-Cell International in?
- What country is Cryo-Cell International based in?
- When did Cryo-Cell International go public?
- Is Cryo-Cell International in the S&P 500?
- Is Cryo-Cell International in the NASDAQ 100?
- Is Cryo-Cell International in the Dow Jones?
- When was Cryo-Cell International's last earnings report?
- When does Cryo-Cell International report earnings?
- Should I buy Cryo-Cell International stock now?
What is the primary business of Cryo-Cell International?
Cryo-Cell International (CCEL) is a company that specializes in stem cell banking. They collect and store umbilical cord blood and tissue for future medical use. This service helps families preserve valuable stem cells that can be used for treatments and therapies for various health conditions.
What is the ticker symbol for Cryo-Cell International?
The ticker symbol for Cryo-Cell International is NASDAQ:CCEL
Does Cryo-Cell International pay dividends?
Yes, Cryo-Cell International pays dividends. The last payment was $0.25, with an ex-dividend date on 15 November 2024
What sector is Cryo-Cell International in?
Cryo-Cell International is in the Healthcare sector
What industry is Cryo-Cell International in?
Cryo-Cell International is in the Medical Care Facilities industry
What country is Cryo-Cell International based in?
Cryo-Cell International is headquartered in United States
When did Cryo-Cell International go public?
Cryo-Cell International's initial public offering (IPO) was on 04 April 1994
Is Cryo-Cell International in the S&P 500?
No, Cryo-Cell International is not included in the S&P 500 index
Is Cryo-Cell International in the NASDAQ 100?
No, Cryo-Cell International is not included in the NASDAQ 100 index
Is Cryo-Cell International in the Dow Jones?
No, Cryo-Cell International is not included in the Dow Jones index
When was Cryo-Cell International's last earnings report?
Cryo-Cell International's most recent earnings report was on 15 October 2024
When does Cryo-Cell International report earnings?
The next expected earnings date for Cryo-Cell International is 28 February 2025
Should I buy Cryo-Cell International stock now?
As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions